Field Medical Director/Sr. Field Medical Director - Northeast

About QED Therapeutics & BridgeBio Pharma

QED Therapeutics, an affiliate of BridgeBio Pharma, focuses on developing targeted treatments for FGFR-driven skeletal dysplasias, particularly Achondroplasia. Achondroplasia is the most common form of genetically-driven short stature, which causes potentially debilitating medical complications. With our experimental therapeutic candidate, infigratinib, we seek to provide an option to children living with Achondroplasia and their families.
 
Our business is inspired by our values:

• PUT PATIENTS FIRST
• LET SCIENCE SPEAK
• EVERY MINUTE COUNTS
• THINK INDEPENDENTLY
• BE RADICALLY TRANSPARENT

FGFR=fibroblast growth factor receptor.

BridgeBio is a biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. We bridge the gap between remarkable advancements in genetic science in academic institutions and the delivery of meaningful medicines to patients. Founded in 2015, the company has built a portfolio of 30+ drug development programs ranging from preclinical to late-stage development in multiple therapeutic areas including genetic dermatology, precision oncology, cardiology, endocrinology, neurology, pulmonology, and renal disease, with two approved drugs.

Our focus on scientific excellence and rapid execution aims to translate today’s discoveries into tomorrow’s medicines. We have U.S. offices in San Francisco, Palo Alto, Raleigh, and with small satellites in other parts of the country. We also have international offices in Montreal, Canada, and Zug, Switzerland, and are expanding across Europe.

To learn more about our story and company culture, visit us at https://www.qedtx.com/ | https://bridgebio.com 

Who You Are

The Field Medical Director/Sr. Field Medical Director - Northeast is a field-based scientific expert responsible for communicating with a variety of internal and external stakeholders, providing medical and scientific information on the appropriate utilization of therapy(s), and advancing therapeutic disease state knowledge. The FMD/Sr. FMD is a core member of the Medical Affairs Team, leveraging a scientific approach aligned with medical affairs objectives and therapeutic area medical plans.

The Field Medical Director/Sr. Field Medical Director - Northeast will be experienced in working in a fast-paced, highly collaborative environment, specifically with product launch planning, rare disorders, or underdiagnosed patient populations.  This includes developing and executing a comprehensive territory medical plan, attending conferences, delivering scientific presentations, and scientific exchange with physicians and other healthcare providers.  This role will be critical to cultivating relationships and establishing professional collaborations with academic researchers, therapeutic area leaders, relevant research centers, organizations, and clinical care teams.

This position reports to the National Head, Field Medical Affairs, and will require extensive travel, sometimes involving weekends.

Responsibilities

Assigned Territory focused responsibilities:

Territory Strategy and Planning

• Collaborate with the National Head, Field Medical Affairs in the development and execution of scientific plans within their territory to meet company-defined goals within corporate and regulatory guidelines for products both marketed and in development
• Lead the execution of Medical Affairs strategic plans in the territory
• Maintain clinical/technical expertise in specific therapeutic areas; review scientific journals, attend scientific and key technical meetings in the territory, and share learnings with key stakeholders
• Serve as a resource to the commercial team on scientific/market intelligence
• Proactively provide feedback on emerging clinical/competitive trends

Local Market key relationship, scientific knowledge, and access development

• Identify and build advocacy with key investigators and key accounts to facilitate mutually beneficial research on infigratinib
• Develop field-based relationships with KOLs, HCPs, Clinics, etc., in support of strategic plans and may contribute to HCP strategies for multiple brands
• Develops, maintains, and leverages strategic relationships with professional societies consistent with Medical Affairs goals
• Develops, maintains, and leverages strategic relationships with the scientific board of patient advocacy groups c